Veru Stock - CEO Interview with Mitchell Steiner скачать в хорошем качестве

Veru Stock - CEO Interview with Mitchell Steiner

Justin interviews Mitchell Steiner, Veru Inc. CEO (NASDAQ: VERU) Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass thereby improving body composition and physical function. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. For more information, visit https://verupharma.com Trade With Justin ➡️ https://thealgo.com Business Inquiry ➡️ [email protected] #pharmastocks #stockstobuy #topstocks Disclaimer: This video is not investment advice. For our full disclaimer, please visit https://blazecapital.com/disclaimer Sponsored Content: Blaze Capital (Justin Caron) was paid $2,500 USD by a 3rd party for a marketing package, that includes this video. Justin Caron does own a position in Veru Inc. (NASDAQ: VERU). Justin Caron purchased shares in the open market - in the days before this video was published - which may have impacted the share price in Veru Inc. (NASDAQ: VERU).